Work

Tumorska kaheksija kao predskazatelj kemoterapijske toksičnosti i vremena do tumorske progresije u bolesnika s proširenim karcinomom pluća [Cancer cachexia as a predictor of chemotherapy toxicity and time-to-tumor progression in patients with advanced non-small cell lung cancer]

Year: 2017
Type: dissertation
Study design: Observational Study
Abstract: Background. Cancer cachexia and sarcopenia are frequently observed in cancer patients and associated with poor survival. The majority of studies of cancer cachexia and sarcopenia have been done in patients with solid tumors of different origin, and there are currently no good predictors of the benefit of chemotherapy or factors that predict survival in advanced cancer. \nThe purpose of our prospective study was to evaluate prevalence of cachexia and sarcopenia using international consensus definition and criteria for diagnosis in patients with diagnosed advanced non-small cell lung cancer (NSCLC) stage IIIB and IV and their relation to chemotherapy toxicity and survival prediction. A secondary aim was to compare several biochemical and haematological markers (CRP, IL-6, protein and albumin) with time to tumor progression in order to assess prognostic value or to guide a treatment. \nPatients and Methods. Between December 2013 and April 2015, the prospective cohort study of one hundred Caucasian patients with advanced NSCLC stage IIIB or IV, who were referred consecutively to Department for Respiratory Diseases “Jordanovac” was evaluated. Anthropometric measurements and biochemical / haematological data (CRP, albumin, protein, IL-6, haemoglobin) together with body composition measurements (total muscle cross sectional area, lumbar skeletal muscle index) were obtained for each patient before starting with platinum-doublet therapy. Skeletal muscle cross-sectional area at the third lumbar vertebra was measured by computerized tomography, and sarcopenia was defined using a previously published cut-off point. Toxicity was assessed after cycle 1 of treatment and time-to-tumor progression was determined prospectively. \nResults. One hundred patients with advanced lung cancer were recruited: 67 were male, median age was 64 years. The median time to disease progression was 187 days. The prevalence of cachexia and sarcopenia in study cohort was 69 %, and 47 %, respectively. CRP, IL-6 and albumin concentration in cachectic, compared to non-cachectic patients demonstrated statistically significant difference (p = 0,020, p = 0,040, p = 0,003). Cachexia and sarcopenia were not found to be predictors of chemotoxicity nor time to tumor progression. On the contrary, albumin concentration with established cut-off point of 37.5 g/L was clearly proved as the predictive factor of both chemotoxicity (OR (95% CI) = 0.85; p < 0.001) and survival (HR (95% CI) = 0,55). \nConclusion. Albumin level has shown to be more important predictive marker of chemotherapy toxicity and survival than cachexia and sarcopenia. This approach in clinical settings can be used to guide the choice of oncologic treatment.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2913136044
Cites: 93
Cited by:
Related to: 10